Journal List > J Rheum Dis > v.18(4) > 1063933

Lee, Kim, Na, Lee, Suh, Cheon, Kang, Kim, and Lee: A Case of Steroid and Methotrexate-Resistant Eosinophilic Fasciitis Treated with Adalimumab

Abstract

Eosinophilic fasciitis (EF) is a rare fibrosing disorder characterized by painful swelling and induration of the limbs and trunk, characteristic histology with sclerosis and lymphocytic inflammation affecting the fascia. The cause and pathogenesis of EF are still unknown and current therapies include glucocorticoids with or without use of immunosuppressive agents. Recently, there have been several case reports documenting the efficacy of a TNF alpha inhibitor in EF following a steroid-resistant disease course. However, there has been no report on the experience in treatment of EF with a TNF alpha inhibitor in Korea. Hence, we report a case of steroid and methotrexate-re-sistant EF which was successfully treated with adalimumab, along with a review of the relevant articles.

References

1. Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians. 1975; 88:70–86.
2. Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum. 1988; 17:221–31.
crossref
3. Helfman T, Falanga V. Eosinophilic fasciitis. Clin Dermatol. 1994; 12:449–55.
crossref
4. Baumann F, Brühlmann P, Andreisek G, Michel BA, Marincek B, Weishaupt D. MRI for diagnosis and monitoring of patients with eosinophilic fasciitis. AJR Am J Roentgenol. 2005; 184:169–74.
crossref
5. Barnes L, Rodnan GP, Medsger TA, Short D. Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol. 1979; 96:493–518.
6. Pouplin S, Daragon A, Le Loët X. Treatment of eosinophilic fasciitis with methotrexate. J Rheumatol. 1998; 25:606–7.
7. Bukiej A, Dropiński J, Dyduch G, Szczeklik A. Eosinophilic fasciitis successfully treated with cyclosporine. Clin Rheumatol. 2005; 24:634–6.
crossref
8. Whang YJ, Kim KM, Oh SJ, Jang KY, Lee SI, Yoo WH, et al. Diagnostic availability of ultrasonography and the effects of methotrexate therapy in patients with eosinophilic fasciitis: report of two cases. J Korean Rheum Assoc. 2006; 13:56–63.
9. Khanna D, Agrawal H, Clements PJ. Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. Rheumatology (Oxford). 2010; 49:1184–8.
crossref
10. Liou CH, Huang GS, Taylor JA, Juan CJ, Gao HW, Chen CY. Eosinophilic fasciitis in a military recruit: MRI evaluation with clinical correlation. Skeletal Radiol. 2003; 32:52–7.
crossref
11. Barnes L, Rodnan GP, Medsger TA, Short D. Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol. 1979; 96:493–518.
12. Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol. 2008; 47:29–35.
crossref
13. Tzaribachev N, Holzer U, Schedel J, Maier V, Klein R, Kuemmerle-Deschner J. Infliximab effective in ste-roid-dependent juvenile eosinophilic fasciitis. Rheumatology (Oxford). 2008; 47:930–2.
crossref
14. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma- associated joint disease. J Rheumatol. 2007; 34:1636–7.

Figure 1.
(A) The initial MRI shows enhancement in the posterior layers of the thoracolumbar fascia (arrow). (B) The followup MRI shows an increase in the enhancement in the posterior layers of the thoracolumbar fascia. (C) After treatment with anti TNF-α agent, the MRI shows marked improvement in fasciitis.
jrd-18-306f1.tif
Figure 2.
Superficial fascia taken from the left vastus intermedius shows dense fibrous tissue with inflammatory cell infiltration in the thickened fascia (H&E stain, ×100).
jrd-18-306f2.tif
Figure 3.
Changes in the eosinophil count (%) during treatment.
jrd-18-306f3.tif
Table 1.
Cases of eosinophilic fasciitis treated with anti-TNF-α agent
Patient Age/sex Anti-TNF-α agent Treatment dose Treatment duration Reference
1 46/F Infliximab 3 mg/kg every 8 weeks, 3 years 9
      increased to 5 mg/kg  
2 61/F Infliximab 3 mg/kg q 8 weeks 3 years 9
3 61/F Infliximab 3 mg/kg q 8 weeks 7 months 9
4 12/M Infliximab 300 mg q 4 weeks 1 year 13
5 21/M Adalimumab 40 mg q 2 weeks 7 months Present case

Tumor necrosis factor

TOOLS
Similar articles